Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX Concentrate

Brief Report15 October 1991Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX ConcentrateTerence Hadley, MD, Benjamin Djulbegovic, MD, PhDTerence Hadley, MDSearch for more papers by this author, Benjamin Djulbegovic, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-8-621 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPatients with hemophilia B can be effectively treated with prothrombin complex concentrates (factor IX complex) that contain factors II, VII, IX, and X (1). A complication of therapy with factor IX complex is disseminated intravascular coagulation, attributed in part to activated factors in factor IX complex (2). We describe a patient with hemophilia B who developed disseminated intravascular coagulation while being treated with factor IX complex for a cerebellar hemorrhage. The patient's therapy was switched from factor IX complex to monoclonal antibody-purified factor IX (Mononine, Armour, Blue Bell, Pennsylvania), and the disseminated intravascular coagulation resolved....References1. Aronson D. Factor IX complex. Semin Thromb Hemost. 1979;6:28-43. CrossrefMedlineGoogle Scholar2. CampbellNeffBowdler ESA. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena. Transfusion. 1978;18:94-7. CrossrefMedlineGoogle Scholar3. Hultin M. Activated clotting factors in factor IX concentrates. Blood. 1979;54:1028-38. CrossrefMedlineGoogle Scholar4. MannucciBauerGringeriBarzegarBottassoSimoni PKASBL. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 1990;76:2540-5. CrossrefMedlineGoogle Scholar5. ConlanHoots MW. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol. 1990;35:203-7. CrossrefMedlineGoogle Scholar6. KimMcMillanWhiteBergmanSaidi HCGGP. Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B. Semin Hematol. 1990;27(Suppl 2):30-5. MedlineGoogle Scholar7. KimMattsEiseleCzachurSaidi HLJMP. Comparative thrombogenicity of monoclonal-antibody immunoaffinity purified factor IX and prothrombin complex concentrate [Abstract]. Blood. 1990;76: 425a. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Terence Hadley, MD; Benjamin Djulbegovic, MD, PhDAffiliations: From the University of Louisville, J. G. Brown Cancer Center, Louisville, Kentucky. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUse of Recombinant, Activated Factor VII in the Treatment of Congenital Factor VII DeficienciesEfficacy and safety of continuous infusion of Mononine® during five surgical procedures in three hemophilic patientsCombined factor IX and protein C deficiency in a child: Thrombogenic effects of two factor IX concentratesCurrent Management of Hemophilia BTreatment of hemophilia b: Serendipitous use of continuous infusion coagulation factor IXHemophilia 15 October 1991Volume 115, Issue 8Page: 621-622KeywordsDisseminated intravascular coagulationHematology and oncologyHemophilia BHemorrhage ePublished: 1 December 2008 Issue Published: 15 October 1991 PDF downloadLoading ...